Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

NCT03561883 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

609

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Reflux Disease (GERD)

Interventions

DRUG: IW-3718
DRUG: placebo
DRUG: Standard-dose PPIs QD

Sponsor

Ironwood Pharmaceuticals, Inc.